Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
May 13, 2019 08:15 ET
|
Minerva Neurosciences, Inc
Potential first-in-class, oral specific orexin-2 inhibitor demonstrates statistically significant improvement in MADRS scores at 6 weeks compared to placebo Well tolerated, with adverse events similar...
Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
May 06, 2019 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
April 29, 2019 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
April 11, 2019 08:30 ET
|
Minerva Neurosciences, Inc
Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF Data presented at 2019 Congress of the Schizophrenia International Research Society WALTHAM,...
Minerva Neurosciences to Host Webcast Event on Schizophrenia
March 18, 2019 08:30 ET
|
Minerva Neurosciences, Inc
Decision Resources Group to provide review of the disease landscape and forecast Key opinion leader to discuss negative symptoms in schizophrenia Minerva to outline roluperidone’s potential position...
Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates
March 12, 2019 07:30 ET
|
Minerva Neurosciences, Inc
Recruitment active in five late-stage trials with three compounds directed toward significant unmet medical needs Target indications include schizophrenia, major depressive disorder and insomnia...
Minerva Neurosciences Announces New Patent Application for MIN-117 Related to Broad Effect on Pain
November 28, 2018 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018
November 21, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers
November 19, 2018 08:00 ET
|
Minerva Neurosciences, Inc
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe...
Minerva Neurosciences to Present at Jefferies London Healthcare Conference on November 14, 2018
November 07, 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...